IONIS-GCCRRx
IONIS-GCCRRx, also known as ISIS-426115, is an antiglucocorticoid which is under development by Ionis Pharmaceuticals (formerly Isis Pharmaceuticals) for the treatment of diabetes mellitus type 2.[1][2] It has also been under investigation for the treatment of Cushing's syndrome, but no development has been reported.[1] The drug is an antisense oligonucleotide against the glucocorticoid receptor.[1] As of December 2017, it is in phase II clinical trials for diabetes mellitus type 2.[1]
Clinical data | |
---|---|
Other names | ISIS-426115; ISIS-GCCRRx |
Drug class | Antiglucocorticoid |
References
- "IONIS GCCRRx - AdisInsight". adisinsight.springer.com.
- Chikara, Gaurav; Sharma, Pramod Kumar; Dwivedi, Pradeep; Charan, Jaykaran; Ambwani, Sneha; Singh, Surjit (2017). "A Narrative Review of Potential Future Antidiabetic Drugs: Should We Expect More?". Indian Journal of Clinical Biochemistry. 33 (2): 121–131. doi:10.1007/s12291-017-0668-z. ISSN 0970-1915. PMC 5891460. PMID 29651202.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.